Studies don't support use of triweekly degludec

07/12/2013 | Medscape (free registration)

Type 2 diabetes patients who received triweekly degludec dosing had inferior glycemic control and a higher risk of hypoglycemia within the first 24 hours compared with those who were on once-daily glargine, two late-stage trials indicated. Evidence does not support the use of a three-times-a-week dosing of insulin degludec, researchers concluded. The findings were published in the Lancet Diabetes-Endocrinology.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Actuary
NTA Life
Addison, TX
Vice President - Government Products
Health Alliance Plan
Detroit, MI